ALX Oncology (NASDAQ:ALXO) Receives “Buy” Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of ALX Oncology (NASDAQ:ALXO) in a research note issued to investors on Wednesday morning,Benzinga reports. The firm currently has a $25.00 price target on the stock.

Separately, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of ALX Oncology in a research report on Tuesday, November 12th. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to MarketBeat.com, ALX Oncology currently has a consensus rating of “Moderate Buy” and an average target price of $8.50.

ALX Oncology Trading Up 9.5 %

ALX Oncology stock opened at $1.62 on Wednesday. The company has a quick ratio of 4.82, a current ratio of 4.82 and a debt-to-equity ratio of 0.07. ALX Oncology has a 12 month low of $1.19 and a 12 month high of $17.83. The company’s fifty day simple moving average is $1.49 and its 200-day simple moving average is $3.32. The stock has a market cap of $85.44 million, a P/E ratio of -0.54 and a beta of 1.04.

Insider Activity

In related news, Director Rekha Hemrajani purchased 30,000 shares of the firm’s stock in a transaction dated Monday, December 2nd. The stock was bought at an average price of $1.55 per share, for a total transaction of $46,500.00. Following the purchase, the director now owns 33,000 shares in the company, valued at $51,150. The trade was a 1,000.00 % increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 33.40% of the stock is owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. Point72 Asset Management L.P. bought a new stake in ALX Oncology during the second quarter worth approximately $1,834,000. GSA Capital Partners LLP acquired a new stake in shares of ALX Oncology in the third quarter worth $88,000. Marshall Wace LLP boosted its holdings in shares of ALX Oncology by 423.0% during the 2nd quarter. Marshall Wace LLP now owns 635,679 shares of the company’s stock worth $3,833,000 after buying an additional 514,133 shares during the period. SG Americas Securities LLC boosted its holdings in shares of ALX Oncology by 33.6% during the 3rd quarter. SG Americas Securities LLC now owns 27,394 shares of the company’s stock worth $50,000 after buying an additional 6,888 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its stake in ALX Oncology by 394.8% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,517 shares of the company’s stock valued at $39,000 after buying an additional 5,200 shares during the last quarter. 97.97% of the stock is owned by institutional investors.

ALX Oncology Company Profile

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.